Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.
AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...
AstraZeneca’s Ultomiris met its first co-primary endpoint in a Phase III trial for IgA nephropathy, significantly reducing urine protein levels by week 34. The result supports the drug’s potential as ...